Payment overview · 2025
General Payments
$735.17
32 reported records · 10 companies
Healthcare provider profile · identity verified
Nathaniel James Vinje, DO
Allopathic & Osteopathic Physicians|Internal Medicine · INVERNESS, FL · NPI 1679909204
Verified facts
What the public records show
CMS Open Payments records show Nathaniel James Vinje, DO received $735.17 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Paxlovid, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $236.49 | 32.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $171.00 | 23.3% | 13 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $97.30 | 13.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.64 | 6.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.81 | 5.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.44 | 5.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.85 | 4.3% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $29.91 | 4.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.87 | 4.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.86 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $735.17 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $188.95 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $171.00 | 13 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $72.73 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.96 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.54 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $46.64 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.85 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $29.91 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.87 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 176 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
176 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 904 | 279 |
| Levothyroxine Sodium | Levothyroxine Sodium | 754 | 228 |
| Losartan Potassium | Losartan Potassium | 641 | 210 |
| Lisinopril | Lisinopril | 615 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 588 | 195 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 519 | 174 |
| Omeprazole | Omeprazole | 472 | 165 |
| Gabapentin | Gabapentin | 443 | 163 |
| Metoprolol Tartrate | Metoprolol Tartrate | 380 | 125 |
| Metformin Hcl | Metformin Hcl | 368 | 121 |
| Tramadol Hcl | Tramadol Hcl | 334 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 328 | 125 |
| Trazodone Hcl | Trazodone Hcl | 325 | 110 |
| Simvastatin | Simvastatin | 281 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 89 |
| Meloxicam | Meloxicam | 261 | 103 |
| Glipizide | Glipizide | 248 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 226 | 85 |
| Methylprednisolone | Methylprednisolone | 224 | 178 |
| Furosemide | Furosemide | 214 | 84 |
| Pioglitazone Hcl | Pioglitazone Hcl | 210 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 204 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 186 | 75 |
| Tizanidine Hcl | Tizanidine Hcl | 183 | 76 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 176 | 52 |
| Montelukast Sodium | Montelukast Sodium | 152 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 47 |
| Alendronate Sodium | Alendronate Sodium | 146 | 54 |
| Carvedilol | Carvedilol | 143 | 46 |
| Azithromycin | Azithromycin | 142 | 128 |
| Mirtazapine | Mirtazapine | 136 | 53 |
| Famotidine | Famotidine | 132 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 38 |
| Ibuprofen | Ibuprofen | 124 | 79 |
| Ozempic | Semaglutide | 120 | 29 |
| Finasteride | Finasteride | 116 | 34 |
| Atenolol | Atenolol | 111 | 33 |
| Allopurinol | Allopurinol | 110 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 34 |
| Sertraline Hcl | Sertraline Hcl | 107 | 31 |
| Buspirone Hcl | Buspirone Hcl | 106 | 41 |
| Eliquis | Apixaban | 105 | 37 |
| Fenofibrate | Fenofibrate | 101 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 54 |
| Ezetimibe | Ezetimibe | 89 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 74 |
| Baclofen | Baclofen | 83 | 28 |
| Glimepiride | Glimepiride | 80 | 28 |
| Oxybutynin Chloride | Oxybutynin Chloride | 80 | 35 |
| Amoxicillin | Amoxicillin | 74 | 64 |
| Prednisone | Prednisone | 73 | 46 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 22 |
| Venlafaxine Hcl | Venlafaxine Hcl | 72 | 24 |
| Clonidine Hcl | Clonidine Hcl | 71 | 19 |
| Xarelto | Rivaroxaban | 68 | 21 |
| Sildenafil Citrate | Sildenafil Citrate | 65 | 23 |
| Spironolactone | Spironolactone | 64 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 53 |
| Potassium Chloride | Potassium Chloride | 60 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 18 |
| Alprazolam | Alprazolam | 57 | 14 |
| Meclizine Hcl | Meclizine Hcl | 57 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 17 |
| Pregabalin | Pregabalin | 46 | 19 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 21 |
| Ondansetron Odt | Ondansetron | 44 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 17 |
| Enalapril Maleate | Enalapril Maleate | 43 | 16 |
| Jardiance | Empagliflozin | 43 | 14 |
| Celecoxib | Celecoxib | 42 | 13 |
| Lovastatin | Lovastatin | 41 | 11 |
| Metformin Hcl Er | Metformin Hcl | 41 | 17 |
| Nabumetone | Nabumetone | 40 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Topiramate | Topiramate | 38 | 18 |
| Synthroid | Levothyroxine Sodium | 37 | 14 |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 33 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | 17 |
| Chlorthalidone | Chlorthalidone | 35 | 11 |
| Donepezil Hcl | Donepezil Hcl | 35 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 30 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Cephalexin | Cephalexin | 33 | 30 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 14 |
| Fluconazole | Fluconazole | 32 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 14 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | 14 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Nystatin | Nystatin | 29 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | 15 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 28 | 12 |
| Warfarin Sodium | Warfarin Sodium | 28 | 11 |
| Doxepin Hcl | Doxepin Hcl | 27 | 14 |
| Acyclovir | Acyclovir | 26 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Nitroglycerin | Nitroglycerin | 20 | 13 |
| Promethazine Hcl | Promethazine Hcl | 20 | 14 |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Benzonatate | Benzonatate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $735.17 · 32 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Arikayce, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, GEMTESA, JARDIANCE, Ozempic, PAXLOVID, PREVNAR 20, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error